Stocks and Investing Stocks and Investing
Fri, September 30, 2022

David Risinger Maintained (ABBV) at Sell with Decreased Target to $135 on, Sep 30th, 2022


Published on 2024-10-27 23:09:08 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of SVB Leerink, Maintained "AbbVie Inc." (ABBV) at Sell with Decreased Target from $140 to $135 on, Sep 30th, 2022.

David has made no other calls on ABBV in the last 4 months.



There are 11 other peers that have a rating on ABBV. Out of the 11 peers that are also analyzing ABBV, 5 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $160 on, Monday, August 1st, 2022
  • Colin Bristow of "UBS" Maintained at Hold with Decreased Target to $146 on, Monday, August 1st, 2022
  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Decreased Target to $162 on, Monday, August 1st, 2022
  • Luisa Hector of "Berenberg" Reiterated at Hold and Held Target at $135 on, Friday, July 15th, 2022
  • Geoff Meacham of "B of A Securities" Reiterated at Hold and Held Target at $156 on, Tuesday, June 21st, 2022


These are the ratings of the 6 analyists that currently disagree with David


  • Terence Flynn of "Morgan Stanley" Reiterated at Buy and Held Target at $188 on, Wednesday, September 14th, 2022
  • Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Decreased Target to $155 on, Wednesday, August 24th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $188 on, Monday, August 1st, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $155 on, Monday, August 1st, 2022
  • Gary Nachman of "BMO Capital" Maintained at Buy with Decreased Target to $170 on, Monday, August 1st, 2022
  • Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $160 on, Friday, July 29th, 2022
Contributing Sources